Washington, D.C. 20549









Pursuant to Rule 13a-16 or 15d-16

of the Securities Exchange Act of 1934


November 15, 2018




 (Exact name of Registrant as specified in its charter)



Novo Allé 

DK- 2880, Bagsvaerd 


(Address of principal executive offices)



Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F


Form 20-F [X]           Form 40-F [  ]


Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.


Yes [  ]            No [X]


If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________









Novo Nordisk A/S – Share repurchase programme



Bagsværd, Denmark, 15 November 2018 – On 5 November 2018, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR), also referred to as the Safe Harbour rules. This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 1 February 2018.


Under the programme initiated 5 November 2018, Novo Nordisk will repurchase B shares for an amount of up to DKK 3.2 billion in the period from 6 November 2018 to 30 January 2019.


Since the announcement as of 5 November 2018, the following transactions have been made under the programme:


  Number of
B shares
purchase price
value, DKK
Accumulated, last announcement 0   0
6 November 2018 225,000 282.08 63,468,823
7 November 2018 200,000 287.98 57,595,517
8 November 2018 200,000 292.56 58,512,080
9 November 2018 200,000 295.05 59,010,600
12 November 2018 200,000 297.09 59,418,532
13 November 2018 210,000 296.42 62,249,214
14 November 2018 200,000 293.31 58,662,126
Accumulated under the programme 1,435,000   418,916,892


The details for each transaction made under the share repurchase programme are published on novonordisk.com.




Page 2 of 2



With the transactions stated above, Novo Nordisk owns a total of 50,570,789 B shares of DKK 0.20, corresponding to 2.1% of the share capital, as treasury shares. The total amount of A and B shares in the company is 2,450,000,000 including treasury shares.


Novo Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month period beginning 1 February 2018. As of 14 November 2018, Novo Nordisk has since 1 February 2018 repurchased a total of 40,621,630 B shares at an average share price of DKK 300.97 per B share equal to a transaction value of DKK 12,225,983,763.



Novo Nordisk is a global healthcare company with 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 79 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.



Further information

Anne Margrethe Hauge +45 4442 3450 amhg@novonordisk.com
Ken Inchausti (US) +1 609 240 9429 kiau@novonordisk.com
Peter Hugreffe Ankersen +45 3075 9085 phak@novonordisk.com
Anders Mikkelsen +45 3079 4461 armk@novonordisk.com
Valdemar Borum Svarrer +45 3079 0301 jvls@novonordisk.com
Kristoffer Due Berg +45 3079 2849 krdb@novonordisk.com








Novo Nordisk A/S

Investor Relations

Novo Allé

2880 Bagsværd



+45 4444 8888


CVR no:

24 25 67 90

    Company announcement No 88 / 2018





Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.


Date: November 15, 2018




Lars Fruergaard Jørgensen

Chief Executive Officer